ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 2169

Cost-utility of a Progressive Spacing of Tocilizumab or Abatacept in Patients with Rheumatoid Arthritis in Sustained Remission: A Medico-economic Analysis of the Towards the Lowest Efficacious Dose Trial
Abstract Number: 2170

Systemic Glucocorticoids Are Associated with a Time and Dose-dependent Risk of Major Adverse Cardiovascular Event in Patients with Rheumatoid Arthritis: A Population-based Study
Abstract Number: 2171

Common IL-6 Signaling Is Inhibited by IL-6 Inhibitors and JAK Inhibitors, but Which Is Better at Preventing Bone Destruction in RA?
Abstract Number: 2172

Subcutaneus vs Intravenous Abatacept in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 509 Patients
Abstract Number: 2173

Window of Opportunity in the Treatment of Rheumatoid Arthritis-Interstitial Lung Disease with Abatacept. National Multicenter Study of 509 Patients
Abstract Number: 2174

JAK Inhibitors in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 73 Patients, 55 of Baricitinib
Abstract Number: 2175

Real-World Drug Persistence of GP2015, an Etanercept Biosimilar, in Patients with Rheumatoid Arthritis: Results from the Multi-Country COMPACT Study
Abstract Number: 2176

Cellular and Proteomic Changes Following Administration of Peresolimab, in a Phase 2a Trial in Rheumatoid Arthritis
Abstract Number: 2177

Characterization of Crevicular Fluid Microbiota in Primary Sjögren’s Syndrome
Abstract Number: 2178

Increased Risk of Dementia in Patients with Primary Sjogren’s Syndrome: A Nationwide Population-based Cohort Study
Abstract Number: 2179

Disease Burden of Patients with Primary Sjögren’s Disease: Results from a Multinational Real-World Survey
Abstract Number: 2180

Salivary and Plasma Mitochondrial Double-strand RNAs as a Diagnostic Biomarker for Sjӧgren Syndrome
Abstract Number: 2181

Secretagogue Effect of PDE4 Inhibitor Apremilast on Human Salivary Gland Organoids Obtained from Primary Sjögren’s Syndrome Patients
Abstract Number: 2182

Mitochondrial Alterations in Primary Sjögren´s Syndrome
Abstract Number: 2183

Evolution of Lymphoma Predictors in Primary Sjogren’s Syndrome by Data Driven Analysis in Harmonized Patients

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].